Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729937 · ClinicalTrials.gov registry record · Phase 2
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 2,265
- Enrollment target
NCT00729937 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,265 participants.
The verdict
NCT00729937, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,265 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal outpatient treatment strategy of uncomplicated skin and soft tissue infection (SSTI) in areas of the United States where the prevalence of Community-Acquired Methicillin-Resistant Staphylococcus (S.) aureus (CA-MRSA) is high. Infection with the S. aureus bacteria that is resistant to antibiotics is a cause of SSTIs. Three oral antibiotics will be tested for off patent treatment. Patients will receive Trimethoprim/Sulfamethoxazole (TMP/SMX), placebo (substance containing no medication), clindamycin, or cephalexin or some combination of these. The study population will include 2,235 volunteers, children 13 years of age and over and adults presenting to 5 large urban Emergency Departments. Therapy for acute uncomplicated SSTIs, including abscess, infected wound, and cellulitis will start on the day of enrollment. Participants may be involved in study related procedures for about 9 weeks.
Interventions
- OTHER Placebo
- DRUG Clindamycin
- DRUG Cephalexin
- DRUG Trimethoprim-sulfamethoxazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,265 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729937
The ClinicalTrials.gov registry entry for NCT00729937 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00729937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729937 about?
NCT00729937 is a clinical study titled "Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"". The purpose of this study is to determine the optimal outpatient treatment strategy of uncomplicated skin and soft tissue infection (SSTI) in areas of the United States where the prevalence of Community-Acquired Methicillin-Resistant Staphylococcus (S.) aureus (CA-MRSA) is high. Infection with the S...
What is the current status of trial NCT00729937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,265 participants. The study started on 2009-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00729937?
The interventions under investigation include: Placebo (OTHER), Clindamycin (DRUG), Cephalexin (DRUG), Trimethoprim-sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT00729937?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.